Research team discovers new role of cerebellum in coordinating the brain network essential for social recognition memory

by Alex Smith,University of Minnesota Medical SchoolAltered c-Fos expression by chemogenetic excitation of MLIs in cerebellar lobules IV-VII following the social recognition test.aDe

Updated on: January 10,2024

Research team discovers new role of cerebellum in coordinating the brain network essential for social recognition memory

by Alex Smith,University of Minnesota Medical SchoolAltered c-Fos expression by chemogenetic excitation of MLIs in cerebellar lobules IV-VII following the social recognition test.aDe

Updated on:January 10,2024

Consistently exercising 2–3 times a week over the long term linked to lower current insomnia risk

byBritish Medical JournalCredit: Unsplash/CC0 Public DomainConsistently exercising 2–3 times a week over the long term is linked to a lower current risk of insomnia as well as the ability to clo

Updated on: March 27,2024

Consistently exercising 2–3 times a week over the long term linked to lower current insomnia risk

byBritish Medical JournalCredit: Unsplash/CC0 Public DomainConsistently exercising 2–3 times a week over the long term is linked to a lower current risk of insomnia as well as the ability to clo

Updated on:March 27,2024

Mapping the human brain's default mode network: Anatomical study suggests it has widespread influence

Updated on: March 02,2025

Mapping the human brain's default mode network: Anatomical study suggests it has widespread influence

Updated on:March 02,2025

Gantenerumab does not slow clinical decline in early Alzheimer disease, research finds

by Elana GotkineThe use of gantenerumab leads to lower amyloid plaque burden at 116 weeks, but is not associated with slower clinical decline among patients with early Alzheimer disease, according to

Updated on: February 24,2024

Gantenerumab does not slow clinical decline in early Alzheimer disease, research finds

by Elana GotkineThe use of gantenerumab leads to lower amyloid plaque burden at 116 weeks, but is not associated with slower clinical decline among patients with early Alzheimer disease, according to

Updated on:February 24,2024

Preparing for a tough exam? A tough gym workout could help with your studies

Updated on: December 08,2025

Preparing for a tough exam? A tough gym workout could help with your studies

Updated on:December 08,2025

MS treatment that 'resets' immune system may halt disease progression for at least five years

by Imperial College LondonDemyelination by MS. The CD68 colored tissue shows several macrophages in the area of the lesion. Original scale 1:100. Credit:CC BY-SA 3.0Marvin 101/Wikiped

Updated on: April 01,2024

MS treatment that 'resets' immune system may halt disease progression for at least five years

by Imperial College LondonDemyelination by MS. The CD68 colored tissue shows several macrophages in the area of the lesion. Original scale 1:100. Credit:CC BY-SA 3.0Marvin 101/Wikiped

Updated on:April 01,2024

Experimental therapy eases Alzheimer's signs, symptoms in mice

by Carole Tanzer MillerA new cellular therapy improved learning and memory in mice with Alzheimer's disease, researchers report.The therapy—developed at the University of Nebraska Medical Center (

Updated on: February 24,2024

Experimental therapy eases Alzheimer's signs, symptoms in mice

by Carole Tanzer MillerA new cellular therapy improved learning and memory in mice with Alzheimer's disease, researchers report.The therapy—developed at the University of Nebraska Medical Center (

Updated on:February 24,2024

New memory drug moves into Phase 1 clinical study

by National Institutes of HealthAn experimental drug that may improve memory is now being tested in a Phase 1 safety trial. The compound, BPN14770, was developed by Tetra Discovery Partners, with

Updated on: February 27,2024

New memory drug moves into Phase 1 clinical study

by National Institutes of HealthAn experimental drug that may improve memory is now being tested in a Phase 1 safety trial. The compound, BPN14770, was developed by Tetra Discovery Partners, with

Updated on:February 27,2024

FDA approves Vyalev for advanced Parkinson's disease

by Lori SolomonThe U.S. Food and Drug Administration has approved AbbVie's Vyalev (foscarbidopa and foslevodopa) for adults living with advanced Parkinson's disease (PD).Vyalev is the first an

Updated on: November 07,2024

FDA approves Vyalev for advanced Parkinson's disease

by Lori SolomonThe U.S. Food and Drug Administration has approved AbbVie's Vyalev (foscarbidopa and foslevodopa) for adults living with advanced Parkinson's disease (PD).Vyalev is the first an

Updated on:November 07,2024

Helping children and young people isolated by young onset dementia find a voice

by University of SheffieldA pioneering study led by researchers from the University of Sheffield is helping to give a voice to children and young adults who are living with a parent with dementia

Updated on: April 29,2024

Helping children and young people isolated by young onset dementia find a voice

by University of SheffieldA pioneering study led by researchers from the University of Sheffield is helping to give a voice to children and young adults who are living with a parent with dementia

Updated on:April 29,2024

Combination drug therapy shows promise for a treatment-resistant cancer

by Johns Hopkins University School of MedicineChristine Pratilas, M.D., in the lab. Credit: Frederick W. Dubs, Johns Hopkins Pathology Photography & GraphicsA combination of two cancer drugs

Updated on: May 21,2024

Combination drug therapy shows promise for a treatment-resistant cancer

by Johns Hopkins University School of MedicineChristine Pratilas, M.D., in the lab. Credit: Frederick W. Dubs, Johns Hopkins Pathology Photography & GraphicsA combination of two cancer drugs

Updated on:May 21,2024

Serotonin vs. Dopamine - 7 Key Differences Between Pleasure and Happiness

Updated on: July 25,2024

Serotonin vs. Dopamine - 7 Key Differences Between Pleasure and Happiness

Updated on:July 25,2024